Table 1.
Parameter | Example(s) |
---|---|
Species |
Mouse, rat, sheep, pig Precise reporting of strain, genetic background, age |
Perturbation |
Pressure overload, MI by permanent LAD ligation or ischaemia/reperfusion injury, diet, salt loading Precise reporting of duration of intervention and period of ischaemia and pressure overload |
Time course | Reporting the time course of disease progression, with samples taken before and at several time points [acute, subacute (days) and chronic (months)] post‐disease induction |
Assessments | |
Histology |
For instance: Masson, Picrosirius red Percentage of LV tissue affected, sampled ROIs; Use of validated antibodies for immune histology
|
Inflammation glycoproteins‐proteoglycans in the heart at RNA and protein level |
‐ Acute vs. chronic process (duration of disease)? Glycoproteins/proteoglycans:
‐ Quantification of inflammation (myeloperoxidase, CD45‐ and CD68‐staining leucocytes). ‐ Collagen crosslinking enzymes (LOX's) ‐ MMP/TIMPs at transcript level and zymography |
Blood biomarkers |
Galectin‐3 CITP PIIINP ST2 |
Imaging | MRI (T1 mapping, late enhancement fibrosis) |
Functional analyses | Echocardiography and invasive haemodynamics for determining load‐dependent diastolic and systolic function |
CITP, C‐terminal propeptide of procollagen type I; CTGF, connective tissue growth factor; LAD, left anterior descending artery; LOX, lysyl oxidase; LV, left ventricular; MI, myocardial infarction; MMP, matrix metalloproteinase; MRI, magnetic resonance imaging; PIIINP, procollagen type III N‐terminal propeptide; ROI, region of interest; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases.